These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 28379518)

  • 1. Response assessment in high-grade glioma: tumor volume as endpoint.
    Huang R
    Neuro Oncol; 2017 Jun; 19(6):744-745. PubMed ID: 28379518
    [No Abstract]   [Full Text] [Related]  

  • 2. Dynamics of circulating hypoxia-mediated miRNAs and tumor response in patients with high-grade glioma treated with bevacizumab.
    Siegal T; Charbit H; Paldor I; Zelikovitch B; Canello T; Benis A; Wong ML; Morokoff AP; Kaye AH; Lavon I
    J Neurosurg; 2016 Oct; 125(4):1008-1015. PubMed ID: 26799295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Misleading early blood volume changes obtained using ferumoxytol-based magnetic resonance imaging perfusion in high grade glial neoplasms treated with bevacizumab.
    Netto JP; Schwartz D; Varallyay C; Fu R; Hamilton B; Neuwelt EA
    Fluids Barriers CNS; 2016 Dec; 13(1):23. PubMed ID: 27998280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glioma cell VEGFR-2 confers resistance to chemotherapeutic and antiangiogenic treatments in PTEN-deficient glioblastoma.
    Kessler T; Sahm F; Blaes J; Osswald M; Rübmann P; Milford D; Urban S; Jestaedt L; Heiland S; Bendszus M; Hertenstein A; Pfenning PN; Ruiz de Almodóvar C; Wick A; Winkler F; von Deimling A; Platten M; Wick W; Weiler M
    Oncotarget; 2015 Oct; 6(31):31050-68. PubMed ID: 25682871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiangiogenic therapy for high-grade glioma.
    Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N
    Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma.
    Lee EQ; Reardon DA; Schiff D; Drappatz J; Muzikansky A; Grimm SA; Norden AD; Nayak L; Beroukhim R; Rinne ML; Chi AS; Batchelor TT; Hempfling K; McCluskey C; Smith KH; Gaffey SC; Wrigley B; Ligon KL; Raizer JJ; Wen PY
    Neuro Oncol; 2015 Jun; 17(6):862-7. PubMed ID: 25572329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibroblast growth factor 13 regulates glioma cell invasion and is important for bevacizumab-induced glioma invasion.
    Otani Y; Ichikawa T; Kurozumi K; Inoue S; Ishida J; Oka T; Shimizu T; Tomita Y; Hattori Y; Uneda A; Matsumoto Y; Michiue H; Date I
    Oncogene; 2018 Feb; 37(6):777-786. PubMed ID: 29059154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan.
    Zuniga RM; Torcuator R; Jain R; Anderson J; Doyle T; Ellika S; Schultz L; Mikkelsen T
    J Neurooncol; 2009 Feb; 91(3):329-36. PubMed ID: 18953493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multicenter, Phase 1, Dose Escalation Study of Hypofractionated Stereotactic Radiation Therapy With Bevacizumab for Recurrent Glioblastoma and Anaplastic Astrocytoma.
    Clarke J; Neil E; Terziev R; Gutin P; Barani I; Kaley T; Lassman AB; Chan TA; Yamada J; DeAngelis L; Ballangrud A; Young R; Panageas KS; Beal K; Omuro A
    Int J Radiat Oncol Biol Phys; 2017 Nov; 99(4):797-804. PubMed ID: 28870792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Bevacizumab-Related Hyperintense Lesions on Diffusion-Weighted Imaging at Different Locations in a Patient with Malignant Glioma].
    Oshiro S; Wakuta N; Kawai S; Miki K; Shigemori Y
    No Shinkei Geka; 2017 Jun; 45(6):509-517. PubMed ID: 28634311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bevacizumab has differential and dose-dependent effects on glioma blood vessels and tumor cells.
    von Baumgarten L; Brucker D; Tirniceru A; Kienast Y; Grau S; Burgold S; Herms J; Winkler F
    Clin Cancer Res; 2011 Oct; 17(19):6192-205. PubMed ID: 21788357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Evaluation of ADC mapping as an early predictor for tumor response to chemotherapy in recurrent glioma treated with bevacizumab/irinotecan: proof of principle].
    Ringelstein A; Turowski B; Gizewski ER; Schroeteler J; Rapp M; Saleh A; Lanzman RS; Mathys C; Sabel M; Mödder U
    Rofo; 2010 Oct; 182(10):868-72. PubMed ID: 20740393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypervascular tumor volume estimated by comparison to a large-scale cerebral blood volume radiographic atlas predicts survival in recurrent glioblastoma treated with bevacizumab.
    Leu K; Enzmann DR; Woodworth DC; Harris RJ; Tran AN; Lai A; Nghiemphu PL; Pope WB; Cloughesy TF; Ellingson BM
    Cancer Imaging; 2014 Nov; 14(1):31. PubMed ID: 25608485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Controlling tumor invasion: bevacizumab and BMP4 for glioblastoma.
    Rahman M; Azari H; Deleyrolle L; Millette S; Zeng H; Reynolds BA
    Future Oncol; 2013 Sep; 9(9):1389-96. PubMed ID: 23980685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Susceptibility-Weighted Imaging of Glioma: Update on Current Imaging Status and Future Directions.
    Hsu CC; Watkins TW; Kwan GN; Haacke EM
    J Neuroimaging; 2016 Jul; 26(4):383-90. PubMed ID: 27227542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Development of Reduced Diffusion Following Bevacizumab Therapy Identifies Regions of Recurrent Disease in Patients with High-grade Glioma.
    Barajas RF; Butowski NA; Phillips JJ; Aghi MK; Berger MS; Chang SM; Cha S
    Acad Radiol; 2016 Sep; 23(9):1073-82. PubMed ID: 27443507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of angiotensin system inhibitors on survival in newly diagnosed glioma patients and recurrent glioblastoma patients receiving chemotherapy and/or bevacizumab.
    Levin VA; Chan J; Datta M; Yee JL; Jain RK
    J Neurooncol; 2017 Sep; 134(2):325-330. PubMed ID: 28631191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II trial with bevacizumab and irinotecan for patients with primary brain tumors and progression after standard therapy.
    Møller S; Grunnet K; Hansen S; Schultz H; Holmberg M; Sorensen M; Poulsen HS; Lassen U
    Acta Oncol; 2012 Jul; 51(6):797-804. PubMed ID: 22548369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decreased tumor apparent diffusion coefficient correlates with objective response of pediatric low-grade glioma to bevacizumab.
    Hsu CH; Lober RM; Li MD; Partap S; Murphy PA; Barnes PD; Fisher PG; Yeom KW
    J Neurooncol; 2015 May; 122(3):491-6. PubMed ID: 25758812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stereotactic radiosurgery (SRS) in high-grade glioma: judicious selection of small target volumes improves results.
    Bokstein F; Blumenthal DT; Corn BW; Gez E; Matceyevsky D; Shtraus N; Ram Z; Kanner AA
    J Neurooncol; 2016 Feb; 126(3):551-7. PubMed ID: 26603164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.